Microsaic Systems Share Discussion Threads

[ragnarr] 08/7/2021 15:44

Still taking it all so personally I see, and wasting hours of your life trolling MSYS and DVRG

[cocker] 08/7/2021 12:07

Troll, I prefer the truth teller. Today's facts or numbers as the Leprechaun loves so much, did you know Turner Poop are entitled to exercise almost a billion warrants at 0. 1p for services rendered. Who on God's earth would buy shares in this company when associates pockets are being lined with gold.

[ragnarr] 07/7/2021 16:57

Afternoon my little troll friend.

[cocker] 07/7/2021 15:34

WOW, that almost 600 % increase is still 50% below the previous years T/O, so hardly worth a mention. It's also only 20% of annual running costs let alone the huge losses this company is piling up year on year. Probably better to point out more relevant facts like15mill mrk cap which is ridiculous and has how many billion shares in issue, with the usual warrant festival to begin.

[ragnarr] 07/7/2021 15:22

Microsaic Systems sees revenues surge by 594% in 1H21https://www.voxmarkets.co.uk/articles/microsaic-systems-sees-revenues-surge-by-594-in-1h21--efd4640/

[cocker] 06/7/2021 10:27

Jones you need to do more homework my friend. GB took a huge part in the 0.1p heavily discounted placing here, as did his wife I believe. Although if my memory serves me right the funds were from shares she sold in Deep Verge that no one knew about until the market was informed. I'm sure it was all above board and an oversite on her behalf.

[jonesj] 06/7/2021 09:20

I wonder why the directors show so little confidence in this business ?

Holding 1 million shares looks like a lot for the CFO, but at 0.26p, that works out at about £2600. I guess he might not see it as a potential rocket stock.

The new chairman seems not to have bought any shares yet, whilst he holds £2.6m in Deep Verge, which is mentioned as a related party in the RNS today.

[david gruen] 06/7/2021 07:31

06/07/2021 7:00am
UK Regulatory (RNS & others)

Microsaic Systems (LSE:MSYS)
Intraday Stock Chart

Tuesday 6 July 2021

Click Here for more Microsaic Systems Charts.
TIDMMSYS

RNS Number : 2415E

Microsaic Systems plc

06 July 2021

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018) ("UK MAR").

6 July 2021

Microsaic Systems plc

("Microsaic" or the "Company")

Microsaic trading update for H1 2021

Unaudited revenues up 594% on H1 2020 and 52% on H1 2019,

reflecting new business model

Microsaic (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments is delighted to announce that a strategic change of business model early in 2021 has resulted in recovery of growth in revenues, increasing to GBP0.499m in H1 2021, significantly above H1 2020 and that of H1 2019, a pre-pandemic benchmark.

First Half Highlights:

-- Unaudited revenues of GBP0.499m
o 594% increase over H1 2020 (GBP0.072m) and 52% over H1 2019 (GBP0.328m).

-- January: transformative placing which raised GBP5.5m (gross), board changes and strategic shift away from independent development to a commercial strategy with external partners.

-- Five key commercial hires to accelerate revenues on environmental detection of water contamination and in human health markets, delivering real-time on-site monitoring and data analytics with connected Internet of Things ("IoT"), AI and support services.

-- March: commercial agreement with DeepVerge plc ("DeepVerge"; AIM: DVRG), through which Microsaic products and services are being deployed internationally in applications such as water monitoring of chemicals and pathogens, and in support of DeepVerge's rapidly growing Labskin division.

-- May: initial shipments to a new Chinese partner to obtain a medical licence in China for real-time therapeutic monitoring of drugs with commercialisation (including service and reagents revenue sharing) expected in 2022.

-- May: collaboration with Swansea University to combine real-time monitoring of environmental water using AI in determining the link between environmental chemical pollution and human health.

-- June: further order from DeepVerge under the framework agreement
Post Period Events:

-- July: The world first demonstration of real-time monitoring of on-line production of biotherapeutic drugs such as vaccines and anti-cancer treatments using Process Analytical Technology within a Microsaic micro-engineered MS solution.

Ongoing commercial developments

-- Disruptive low-cost and mobile system to detect organic chemicals in water and wastewater adapted for in-field deployment.

-- Detection of volatile contaminants in water, with product demonstration expected in H2 of this year. This significantly expands the reach of applications with mobile capability for environmental regulatory authorities.

-- Multiple collaboration projects, including in-surgery cancer diagnostics, with the aim to secure commercial supply agreements with the potential to revolutionise surgical oncology interventions.

Glenn Tracey, CEO of Microsaic Systems plc, commented:

" I am thrilled to report this transformational performance for the first half of 2021, after the effects that the COVID-19 lockdown had on our customers, employees in 2020 and the financial strain this placed on the Company. The new commercial strategy of collaborating, partnering and revenue sharing has moved the Company away from equipment-only sales. We are now offering integrated real-time data analytics with AI alongside our mass spectroscopy hardware, providing complete solutions such as in-field environmental testing and on-site human diagnostics. The change of strategy and adjustment to a revenue sharing business model has demonstrated solid evidence of sales growth which is expected to continue into H2.

Given the ongoing uncertainties over the effects of further waves of COVID-19 across multiple geographies, the Board remains cautious on short-term forecasting. Accordingly, we will consider whether it is appropriate to reinstate guidance to analysts after publication of the interim results, which is expected to take place during the autumn. However, prospects over the mid-term are looking more positive, with the encouraging first half results being more reflective of the Company's potential, and we look forward to our next scheduled performance update. "

Related party transaction

On 24 March 2021, the Company announced that it had entered into a non-exclusive Framework Services Agreement (the "Agreement") with DeepVerge. The multi-year Agreement provides for the supply by Microsaic to DeepVerge of miniaturised mass spectrometry equipment and services, across DeepVerge's sales, marketing, and distribution channels. The Agreement included an initial order of three units as well as a commitment to purchase further units in connection with the installation of pilot demonstration facilities at DeepVerge's York laboratories (together, the "Orders").

The Company has processed a further smaller purchase order from DeepVerge (the "Further Order") under the Agreement, supplying certain additional mass spectrometry equipment for quality and contamination detection in a range of markets including water and soil analysis. The value of the Further Order is approximately GBP72,000 and constitutes a related party transaction under Rule 13 of the AIM Rules. Additionally, Microsaic is loaning an additional item of equipment to DeepVerge for no consideration, to enable an early evaluation of certain technical aspects of its potential use.

At the time of entering into the Agreement, the independent directors, being Glenn Tracey and Bevan Metcalf, considered, having consulted with the Company's nominated adviser, that the terms of the Agreement, were fair and reasonable insofar as the Company's shareholders are concerned. The independent directors also consider that the terms of the Further Order are consistent with the Agreement and with the terms of the initial Orders, and therefore they consider that the terms of the Further Order continue to be fair and reasonable insofar as shareholders are concerned.

[cashistrash] 06/7/2021 07:23

Looks very positive here

[onehanded] 05/7/2021 09:14

Sold a few here today and taken profit and put into Deepverge DVRG, think Microsaic will need more money in the future, have some left though. Info on Deepverge. The impact will be good in the long run for Microsaic...

[daveboy19] 02/7/2021 16:33

Cheers, ragnarr - appreciate the info.

[ragnarr] 02/7/2021 16:19

Worth a read to understand the implications of todays newsHow to Improve Productivity and Lower Costs with Real-Time Technology at the Point-of-Needhttps://www.microsaic.com/news/how-to-improve-productivity-and-lower-costs-with-real-time-technology-at-the-point-of-need/

[daveboy19] 02/7/2021 15:20

Nice one. Just wish these RNS's contained some figures for us long-suffering PI's.

[janhar] 02/7/2021 14:01

I asked my son who is studying Chemistry at Oxford and he says that real time spectrometry is an amazing achievement - usually takes ages and lots of different processes so it should significantly speed up the development of new drugs.

[daveboy19] 02/7/2021 10:29

Riveting price action to back up today's RNS. All in all, back to sleep zzzz. See you all in 2024.

[ragnarr] 02/7/2021 10:00

https://www.proactiveinvestors.co.uk/companies/news/953981/microsaic-systems-pops-higher-on-vaccine-demonstration-milestone-953981.html

[ragnarr] 02/7/2021 09:36

biotherapeutics, also called biotech drugs or biologics are made from living organisms by using living cells to make or modify protein products to create therapies.Insulin is was the first biotherapeutic medicine and there are now hundreds treating all sorts of illnesses like cancer,heart disease, arthritis and lots moreBiotherapeutics have the ability to target specific molecules within the human body, and have a good track record with patient safety. Manufacturing biotherapeutics is complex, as they are larger compounds in both size and structure, and can be sensitive to environmental conditions. They require sophisticated production and control processes and are dependent upon the host cells of living organisms to produce the necessary active pharmaceutical substances.In a nutshell What MSYS have done is produced the ability to transmit live data via internet-of-things devices to enable constant monitoring of production processes which will speed up the whole process of bringing the drugs to market.Its a very good thing.

[barnes4] 02/7/2021 09:17

Yep
They have got the inch high private I’s all excited
Rofl

[jonesj] 02/7/2021 09:04

Difficult to tell what they have done or what is unique from their RNS.

Can anyone figure out what they have done ?

[david gruen] 02/7/2021 08:34

We now have an uptrend.

[janhar] 02/7/2021 08:30

Fantastic news!

[whiteslice] 02/7/2021 07:28

RNS this morning- what's not to like...

[ragnarr] 30/6/2021 12:12

Microsaic Systems Plc@Microsaic·19hShipping alert! Product on the way to our partners @DeepVerge. Our joint collaborations are really picking up momentum now, covering human and environmental health, and our mini-mass specs on their way to all corners of the world...send us a postcard! #msys @KingfieldElect